Business
Helix BioPharma Chairman resigns
Helix BioPharma Chairman resigns.
About this update from Helix Biopharma Corp.
[{"type":"text","content":"\n\n\n\nAURORA, ON, Oct. 15 /CNW/ - Helix BioPharma Corp. (TSX: HBP / Frankfurt:\nWKN 918864) announced today that Jerome F. McElroy has resigned as Chairman\nand a director of the Company to pursue his retirement interests.\n\n\n"Jerry has had a long involvement with the Company since its amalgamation\nin 1995," said Don Segal, President and Chief Executive Officer. "On behalf of\nthe Company, I thank him for his positive contributions and wish him well with\nhis future endeavors."\n\n\nThe Company has entered into an agreement with Mr. McElroy in respect of\nhis resignation, pursuant to which Mr. McElroy will receive the equivalent of\napproximately one year's salary and benefits in a lump sum payment made today\nof $350,000, plus termination payments for one year of $3,000 per month and\ncontributions to his medical benefits of $12,000 per year for four years.\n\n\nThe Company will designate a new Chairman to succeed Mr. McElroy in the\nnear term.\n\n\nAbout Helix BioPharma Corp.\n\n\nHelix BioPharma Corp. is a biopharmaceutical company specializing in the\nfield of cancer therapy. The Company is actively developing innovative\nproducts for the prevention and treatment of cancer based on its proprietary\ntechnologies. Helix's product development initiatives include its Topical\nInterferon Alpha-2b, for the treatment of conditions caused by the human\npapilloma virus, and its novel L-DOS47 new drug product candidate for the\ntreatment of lung adenocarcinoma. Helix is listed on the Toronto Stock\nExchange under the ticker symbol "HBP".\n\n\nThis News Release contains certain forward-looking statements and\ninformation regarding Helix's product development initiatives, Topical\nInterferon Alpha-2b and L-DOS47. Forward-looking statements and information\ncan be identified by the use of forward-looking terminology such as\n"developing" and "initiatives". Helix's actual results could differ materially\nfrom those anticipated in these forward-looking statements and information as\na result of numerous factors, including without limitation, Helix's need for\nadditional capital in the near term and in future, which may not be available\non acceptable terms or at all; and uncertainty whether Topical Interferon\nAlpha-2b, L-DOS47, or any other product will be developed and marketed\nsucc...